Key Highlights

Risk & Performance

Pipeline Risk Assessment

Pipeline Risk Assessment

Based on historical performance

Moderate Risk

Score: 35/100

Failure Rate

2.1%

1 terminated/withdrawn out of 47 trials

Success Rate

97.5%

+11.0% vs industry average

Late-Stage Pipeline

28%

13 trials in Phase 3/4

Results Transparency

0%

0 of 39 completed trials have results

Key Signals

3 recruiting

Enrollment Performance

Analytics

Phase 2
18(43.9%)
Phase 3
9(22.0%)
Phase 1
8(19.5%)
Phase 4
4(9.8%)
N/A
2(4.9%)
41Total
Phase 2(18)
Phase 3(9)
Phase 1(8)
Phase 4(4)
+1 more

Activity Timeline

Global Presence

Loading network data...

Clinical Trials (47)

Showing 20 of 47 trials
NCT06895486Phase 2Recruiting

Study of Co-administered (Types 1 & 2) Novel Oral Poliomyelitis Vaccines Evaluation

Role: collaborator

NCT05644184Phase 2Recruiting

Study of a Novel Type 1 Oral Poliomyelitis Vaccine in Bangladesh

Role: collaborator

NCT06114641Phase 4Completed

Effectiveness & Safety of Ovine Enoxaparin Sodium to Originator Enoxaparin in Non-ST-Segment Elevation ACS Patients

Role: lead

NCT05482295Phase 3Not Yet Recruiting

Immunogenicity and Safety Following In-House Recombinant Hepatitis B Vaccine in Indonesian Population (Phase III)

Role: lead

NCT05482282Phase 3Withdrawn

Immunogenicity and Safety of DTP-HB-Hib Using New Hepatitis B Bulk (Bio Farma)

Role: lead

NCT05933278Phase 2Completed

Homologous Booster Study of COVID-19 Protein Subunit Recombinant Vaccine

Role: lead

NCT05546502Phase 3Completed

Safety and Immunogenicity of SARS-CoV-2 Protein Subunit Recombinant Vaccine in Healthy Children

Role: lead

NCT04741828Phase 2Completed

Persistence and Long-Term Protection of Vi Antibodies Induced by Vi-DT Conjugate Vaccines in Indonesian

Role: lead

NCT06921460Not Yet Recruiting

Long-Term Protection of Vi Antibodies Induced by Bio TCV in Indonesian Population Compared to PQed TCV

Role: lead

NCT05727215Phase 2Completed

Heterologous Booster Study of COVID-19 Protein Subunit Recombinant Vaccine in Children 12-17 Years of Age

Role: lead

NCT05525208Phase 2Completed

Booster Study of COVID-19 Protein Subunit Recombinant Vaccine

Role: lead

NCT06690502Completed

Post Authorization Safety Profile of Booster IndoVac COVID-19 Vaccination

Role: lead

NCT06690515Phase 1Not Yet Recruiting

Phase I/II, Open Label, Randomized, Safety and Immunogenicity Following DTwP-Hepatitis B-Hib-IPV Vaccine (Bio Farma) in Indonesian Infants

Role: lead

NCT05654467Phase 2Recruiting

Study of a Novel Type 3 Oral Poliomyelitis Vaccine in Panama

Role: collaborator

NCT05433285Phase 3Completed

Immuno-bridging Study of COVID-19 Protein Subunit Recombinant Vaccine

Role: lead

NCT04185545Phase 3Completed

Efficacy, Safety and Immunogenicity of Rotavirus RV3 Vaccine (Bio Farma) in Neonates

Role: lead

NCT06006858Completed

Post Authorization Safety Study Moderna COVID-19 Primary Vaccine

Role: lead

NCT06053853Phase 4Completed

Post Marketing Surveillance of Diphtheria Antitoxin (DAT)

Role: lead

NCT06111911Not ApplicableCompleted

Detection of High-Risk HPV in Urine and Cervical Swab Specimen Using HPV Diagnostic Kit (Bio Farma)

Role: lead

NCT05657769Not ApplicableUnknown

Preventive Care System Application Effectiveness Study on the Treatment of Diabetic Patients in Bandung

Role: lead